On April 3, 2026, AEON Biopharma, Inc. disclosed in an 8-K filing that it received a notice from NYSE American LLC indicating that the company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide. This section requires listed companies to maintain stockholders' equity of at least $4 million if they have reported losses from continuing operations and/or net losses in three of their four most recent fiscal years. As of December 31, 2025, AEON reported a stockholders' deficit of approximately $55 million, which triggered this notice.

This notice follows a previous notification received on February 3, 2025, regarding non-compliance with Section 1003(a)(i), which requires a minimum stockholders' equity of $2 million under similar circumstances. In response to the earlier notice, AEON submitted a plan to regain compliance, which was accepted by NYSE American, granting the company until August 3, 2026, to meet the necessary requirements.

Despite the current notice, AEON's Class A Common Stock will continue to be listed and traded on NYSE American during the plan period, although it will carry a '.BC' indicator to denote its non-compliance status. The company remains committed to executing its plan to regain compliance with the NYSE American listing standards. However, there is no guarantee that AEON will be able to achieve compliance within the required timeframe. The company retains the right to appeal any staff delisting determination as per the Company Guide.

The receipt of this notice does not affect AEON's business operations or its reporting obligations with the SEC. The company has also issued a press release detailing the receipt of this notice, which is included as an exhibit in the 8-K filing. Investors and stakeholders are advised to monitor the company's progress in addressing these compliance issues as they could impact future stock performance.



Press Release distribution
National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.